Management of Henoch-Schönlein Purpura in an 8-Year-Old Female
For an 8-year-old female with HSP, management should be primarily supportive with close monitoring for renal involvement, reserving corticosteroids specifically for severe gastrointestinal symptoms or significant renal disease (persistent proteinuria >1 g/day/1.73m²), while avoiding corticosteroids for prevention of nephritis. 1
Initial Assessment and Risk Stratification
Upon diagnosis, immediately assess for:
- Severity of skin manifestations (palpable purpura distribution and extent)
- Joint involvement (arthritis/arthralgia severity)
- Gastrointestinal symptoms (abdominal pain severity, presence of GI bleeding)
- Renal involvement (urinalysis for hematuria and proteinuria, blood pressure)
Children ≥7 years old and those with severe GI symptoms have significantly higher risk of developing renal involvement and nephrotic syndrome 2, making this 8-year-old patient particularly important to monitor closely.
Treatment Algorithm Based on Disease Severity
Mild HSP (Purpura ± Mild Joint Pain, No GI or Renal Involvement)
- Supportive care only - approximately two-thirds of children improve spontaneously 1
- NSAIDs or paracetamol for joint symptoms 3
- Do NOT use corticosteroids - there is Level 1B evidence that corticosteroids should not be used to prevent HSP nephritis 1
- Activity restriction as tolerated
Moderate HSP (Significant Joint Pain or Moderate Abdominal Symptoms)
- Consider short-course corticosteroids for symptom relief
- Prednisone 1-2 mg/kg/day for 2 weeks reduces duration of abdominal pain 4
- Methylprednisolone pulse therapy shows superior efficacy compared to hydrocortisone in moderate disease 5
- Monitor closely for development of renal involvement
Severe HSP (Severe GI Symptoms, Nephrotic Syndrome, or Crescentic Nephritis)
For severe gastrointestinal manifestations:
- Prednisone 1-2 mg/kg/day orally 4
- Consider methylprednisolone pulse therapy for more rapid response 5
For renal involvement:
- Persistent proteinuria 0.5-1 g/day/1.73m²: Start ACE inhibitor or ARB 1
- Persistent proteinuria >1 g/day/1.73m² after ACE inhibitor/ARB trial AND GFR >50 ml/min/1.73m²: Treat with 6-month course of corticosteroid therapy (same protocol as IgA nephropathy) 1
- Crescentic HSP with nephrotic syndrome and/or deteriorating kidney function: Treat aggressively with steroids plus cyclophosphamide, analogous to ANCA vasculitis treatment 1
Critical Monitoring Requirements
Urinalysis monitoring is essential:
- Check urinalysis at diagnosis
- Repeat weekly for first month
- Then monthly for 6 months
- Renal involvement occurs in 26.9-40% of children 2, 4
- 80% of renal involvement presents as microhematuria and mild proteinuria 6
Blood pressure monitoring:
- Check at every visit
- Hypertension indicates more severe renal involvement
Important Caveats and Pitfalls
Avoid these common errors:
Do NOT use corticosteroids prophylactically to prevent nephritis - this has Level 1B evidence showing no benefit 1 and moderate evidence confirms ineffectiveness 7
Do NOT assume early steroid use prevents renal complications - there is no direct association between early steroid doses and long-term prognosis 2
Do NOT miss underlying infections - always consider infectious triggers like giardiasis, especially with prominent GI symptoms 8. Streptococcal pharyngitis is another common trigger 9
Do NOT underestimate risk in this age group - at 8 years old, this patient has higher risk for renal complications compared to younger children 2
Prognosis and Long-Term Follow-Up
- Short-term prognosis is excellent (94% spontaneous resolution in children) 4
- Long-term morbidity depends on renal involvement severity
- Risk of end-stage renal disease: 1-5% overall 4
- Among those with HSP nephritis, 11-30% may develop renal insufficiency 6
- Continue urinalysis monitoring for at least 6 months, as late renal involvement can occur
The key principle: HSP in children is primarily a self-limiting disease requiring supportive care and vigilant monitoring for renal complications, with corticosteroids reserved for specific indications (severe GI symptoms or significant renal disease) rather than routine prophylactic use. 1, 4